|
[PMID]: | 28783452 |
[Au] Autor: | Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B |
[Ad] Endereço: | Ifigeneia Tzannou, Anastasia Papadopoulou, Swati Naik, Kathryn Leung, Caridad A. Martinez, Carlos A. Ramos, George Carrum, Ghadir Sasa, Premal Lulla, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, Bambi J. Grilley, Robert A. Krance, Stephen Gottschalk, Malcolm K. Brenner, Cliona M. Rooney, Helen E. |
[Ti] Título: | Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. |
[So] Source: | J Clin Oncol;35(31):3547-3557, 2017 Nov 01. | [Is] ISSN: | 1527-7755 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | Purpose Improvement of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from severe viral infections. Adoptively transferred virus-specific T cells (VSTs) generated from eligible, third-party donors could provide broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product. Patient and Methods We generated a bank of VSTs that recognized five common viral pathogens: Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and human herpesvirus 6 (HHV-6). The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. Results A single infusion produced a cumulative complete or partial response rate of 92% (95% CI, 78.1% to 98.3%) overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (n = 3). Clinical benefit was achieved in 31 patients treated for one infection and in seven patients treated for multiple coincident infections. Thirteen of 14 patients treated for BKV-associated hemorrhagic cystitis experienced complete resolution of gross hematuria by week 6. Infusions were safe, and only two occurrences of de novo graft-versus host disease (grade 1) were observed. VST tracking by epitope profiling revealed persistence of functional VSTs of third-party origin for up to 12 weeks. Conclusion The use of banked VSTs is a feasible, safe, and effective approach to treat severe and drug-refractory infections after HSCT, including infections from two viruses (BKV and HHV-6) that had never been targeted previously with an off-the-shelf product. Furthermore, the multispecificity of the VSTs ensures extensive antiviral coverage, which facilitates the treatment of patients with multiple infections. |
[Mh] Termos MeSH primário: |
Infecções por Vírus de DNA/terapia Vírus de DNA/imunologia Transplante de Células-Tronco Hematopoéticas/efeitos adversos Transplante de Células-Tronco Hematopoéticas/métodos Imunoterapia Adotiva/métodos Linfócitos T/imunologia Linfócitos T/transplante
|
[Mh] Termos MeSH secundário: |
Adenovírus Humanos/imunologia Adulto Vírus BK/imunologia Infecções por Vírus de DNA/etiologia Infecções por Vírus de DNA/virologia Feminino Herpesvirus Humano 4/imunologia Herpesvirus Humano 6/imunologia Seres Humanos Masculino Transplante Homólogo Resultado do Tratamento
|
[Pt] Tipo de publicação: | CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE |
[Em] Mês de entrada: | 1710 |
[Cu] Atualização por classe: | 171117 |
[Lr] Data última revisão:
| 171117 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170808 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1200/JCO.2017.73.0655 |
|
|
|